CSF IP-10 levels were significantly increased in patients with mild cognitive impairment and mild Alzheimer’s disease but not in patients with severe Alzheimer’s disease (MMSE score <15), as the biomarker appears to decrease with the progression of the disease [211]. This evidence concerns the gene CXCL10 and early-onset autosomal dominant Alzheimer disease.